Skip to content

MCKHealthcare distribution

McKesson

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$1,069.43
Discount category
Pricey
Analysts
Bullish
Next earnings
Feb 3 · · estimated
Pick status
Research only

In short

Thesis
McKesson trades at a premium because investors pay for steady drug distribution profits and buybacks, and EPS growth at its long-term target with a clean Medical-Surgical separation can earn it.
Gap
Slow. The Q3 fiscal 2027 report expected in early February 2027 is the next test, but proof that EPS growth stays at the long-term target comes over several years.

Company guidance: Adjusted EPS of $45.60 to $46.40 for fiscal 2027 (, Q2 fiscal 2027 earnings release (8-K))

Price history

About

McKesson distributes prescription drugs and medical supplies, and it sells services to drug makers, pharmacies and care providers, mostly in the United States and Canada. It has four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions. In Q2 fiscal 2027, which ended on September 30, 2026, revenue was $111.0 billion. North American Pharmaceutical had revenue of $91.4 billion, Oncology & Multispecialty $15.0 billion, Medical-Surgical Solutions $3.1 billion and Prescription Technology Solutions $1.5 billion.

GLP-1 drugs, the class of weight-loss and diabetes drugs, brought about $16 billion of revenue in Q2 fiscal 2027, about 14% of company revenue, up 26% from a year earlier. McKesson reports that revenue in North American Pharmaceutical, so it is not part of the $1.5 billion of Prescription Technology Solutions. That segment sells access services, such as prior authorization, and third-party logistics. Management says its services grow for GLP-1 and non-GLP-1 drugs, but the company does not say what share of the segment's revenue or profit comes from GLP-1 drugs.

Revenue was $403.4 billion in fiscal 2026. Its fiscal year ends on March 31. Funds managed by affiliates of Apollo own about 13% of Medical-Surgical Solutions, and McKesson plans to separate that business into an independent company. The company is based in Irving, Texas, and its shares trade on the New York Stock Exchange.

Thesis

McKesson trades at a premium because investors pay for steady growth in a business with few rivals. Adjusted EPS rose 18% to $39.11 in fiscal 2026, and the company now expects $45.60 to $46.40 for fiscal 2027, a growth of 17% to 19%. Three large distributors deliver most prescription drugs in the United States, and McKesson extended its distribution agreement with CVS Health through June 2032. Buybacks also lift EPS: diluted shares fell 6% in a year to 116.7 million in Q2 fiscal 2027.

In oncology, McKesson works with practices through a management service organization (MSO): an MSO runs the business side of a medical practice, such as purchasing, billing, technology and group purchasing, and the doctors keep the care. The U.S. Oncology Network, which McKesson says serves over 3,400 providers, works this way. The flywheel is simple: a practice that joins the network buys its specialty drugs through McKesson, so each new practice adds distribution volume, and group purchasing, research and technology services give the practice reasons to stay. McKesson says Oncology & Multispecialty revenue rose 24% in Q2 fiscal 2027 because of specialty distribution and higher volumes across its provider platforms.

The company does not say how much distribution volume comes from each new practice. For the premium to be earned, three things must be true. Adjusted EPS must keep growing at or above the long-term target of 13% to 16% a year as oncology and biopharma services grow. The company must separate Medical-Surgical Solutions, integrate Precision Medicine Group and close the Option Care Health investment, which it expects in the first half of 2027, without large new charges.

The opioid liability of $5.2 billion, paid out through 2038, and the class actions after the August 2026 cybersecurity incident must not grow into larger costs. The Q3 fiscal 2027 report, expected in early February 2027, gives the next test, and the fiscal 2028 guidance in May 2027 gives a larger one. If EPS growth slows toward the growth of drug volumes, the premium can shrink over the next two years.

Sum of the parts (AI estimate)

Segments differ in growth and margin, so each one has its own multiple. Value per share: about $984 in the base case, from $832 (low) to $1,137 (high).

Sum of the parts: segments, figures, multiples and values, in USD
PartFigureMultiple (low / base / high)Base value
North American PharmaceuticalAdjusted segment operating profit (EBIT), trailing 12 months to 2026-09-30 (FY2026 3,452 + H1 FY27 1,934 - H1 FY26 1,600). Largest, lowest-margin segment (about 1% of revenue) with company long-term profit growth target of 5% to 8%; EV/EBIT multiples are assumptions because no peer multiple could be sourced from primary documents.$3.8 billion15.0x / 17.0x / 19.0x$64.4 billion
Oncology & MultispecialtyAdjusted segment operating profit (EBIT), trailing 12 months to 2026-09-30 (FY2026 1,435 + H1 FY27 832 - H1 FY26 684). Revenue up 29% in H1 FY27 and company long-term profit growth target of 13% to 16%, so a higher multiple than distribution; multiple is an assumption.$1.6 billion17.0x / 20.0x / 23.0x$31.7 billion
Prescription Technology SolutionsAdjusted segment operating profit (EBIT), trailing 12 months to 2026-09-30 (FY2026 1,129 + H1 FY27 610 - H1 FY26 530). Technology and services margin near 19% of revenue and long-term profit growth target of 10% to 13%, so a software-like multiple; multiple is an assumption.$1.2 billion20.0x / 24.0x / 28.0x$29.0 billion
Medical-Surgical SolutionsAdjusted segment operating profit (EBIT), trailing 12 months to 2026-09-30 (FY2026 1,029 + H1 FY27 420 - H1 FY26 493). Low growth (revenue +5%) and falling profit (Q2 adjusted profit -10%); base multiple is anchored to Apollo's June 2026 investment of about $1.25 billion for about 13% (implied EV about 13x EBIT after about $3.2 billion segment term loans), which is a preferred-equity deal so it is only a rough guide.$956 million11.0x / 13.0x / 15.0x$12.4 billion
Corporate expenses, netAdjusted corporate expenses, trailing 12 months to 2026-09-30 (FY2026 -654 + H1 FY27 -291 - H1 FY26 -289). Unallocated head-office cost is capitalised at about the blended multiple of the segments above; the multiple is an assumption.-$656 million16.0x / 18.0x / 20.0x-$11.8 billion
Cash and cash equivalentsBalance sheet at 2026-09-30, Form 10-Q filed 2026-11-04; includes working-capital cash, so it may be partly needed to run the distribution business.$6.5 billion
Total debtNote 8, Form 10-Q filed 2026-11-04, at 2026-09-30; includes $3.2 billion Medical-Surgical term loans and $153 million lease and other obligations.-$9.2 billion
Opioid and other litigation liabilitiesNote 11, Form 10-Q filed 2026-11-04: $600 million current plus $4,563 million long-term at 2026-09-30; pre-tax, and adjusted profit excludes these charges.-$5.2 billion
Redeemable noncontrolling interestsBalance sheet at 2026-09-30, Form 10-Q filed 2026-11-04; mostly Apollo's 13% of Medical-Surgical Solutions plus Core Ventures and PRISM Vision, at carrying (redemption) value.-$2.6 billion
Noncontrolling interestsBalance sheet at 2026-09-30, Form 10-Q filed 2026-11-04, at book value.-$375 million
Equity value (116.7 million diluted shares)$114.9 billion
How the AI estimate was made

This is a sum-of-the-parts estimate dated 2026-11-21. The method values each segment as enterprise value on adjusted segment operating profit (EBIT before interest and tax). The profit is trailing twelve months to 2026-09-30. It is built from the FY2026 adjusted segment table in the 8-K earnings release of 2026-05-07 and the six-month table in the 8-K earnings release of 2026-11-04, so no analyst estimate is used. McKesson gives only total adjusted EPS guidance for FY2027 ($45.60 to $46.40, raised on 2026-11-04) and long-term segment growth targets (2026-05-07), so segment guidance for FY2027 does not exist and trailing profit is used instead. All multiples are assumptions: I could not source peer multiples from primary documents, because filings do not give market prices of peers. I did not use any outside price targets or fair values. The only market-linked anchor is the Apollo deal for 13% of Medical-Surgical Solutions (Form 10-Q, 2026-11-04). Segments differ in growth and margin: pharmaceutical distribution has about 1% margin and low growth, while Prescription Technology Solutions has about 19% margin and faster growth. Net cash and claims come from the 10-Q balance sheet at 2026-09-30: cash $6,528 million, debt $9,208 million, litigation $5,163 million, redeemable noncontrolling interests $2,563 million and noncontrolling interests $375 million. Diluted shares are 116.7 million, the weighted average for the quarter ended 2026-09-30. The 49% stake in Option Care Health ($1.4 billion, signed 2026-10-05) is not closed, so it is not included. I assume no tax shield on litigation and I count all cash as excess.

AI estimate of . Multiples are assumptions. It is Kevin's research note, not advice.

Checkpoints

  1. Feb 3, 2027 · est.Pending
    Q3 fiscal 2027 results: EPS growth and guidanceAdjusted EPS growth of 15% or more and fiscal 2027 guidance kept or raised pass; slower growth or a guidance cut fails.
  2. May 2027 · est.Pending
    Fiscal 2027 results and fiscal 2028 guidanceFiscal 2028 adjusted EPS guidance with growth inside or above the 13% to 16% target pass; guidance below the target fails.

Every passed and failed checkpoint across all picks

Recent events

  • November 4, 2026McKesson reported Q2 fiscal 2027 results. Revenue rose 8% to $111.0 billion, and adjusted EPS rose 18% to $11.68. Adjusted operating profit of North American Pharmaceutical rose 22%, and revenue of Oncology & Multispecialty rose 24%. Free cash flow was $2.9 billion. The company raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00. It also extended its distribution agreement with CVS Health through June 2032.
  • November 2, 2026McKesson completed the purchase of Precision Medicine Group, a provider of clinical research and biopharma commercialization services, for about $2.25 billion in cash.
  • October 5, 2026McKesson agreed to invest about $1.4 billion in cash for a 49% minority interest in Option Care Health, a home and alternate site infusion provider. Clayton, Dubilier & Rice will hold the other 51%. The company expects the deal to close in the first half of calendar 2027, after approvals by Option Care Health stockholders and regulators.
Show 4 older events
  • August 25, 2026McKesson found a cybersecurity incident in its information systems. Since September 2026, several class action complaints about the protection of health and personal data have been filed against the company in the Northern District of Texas.
  • August 5, 2026McKesson reported Q1 fiscal 2027 results. Revenue rose 8% to $105.4 billion, and adjusted EPS rose 20% to $9.93. GAAP EPS fell to $5.15 because of a $293 million adjustment to the redemption value of the Apollo interest in Medical-Surgical Solutions. The board raised the quarterly dividend by 15% to $0.94 per share, and the company raised its fiscal 2027 adjusted EPS guidance to $44.20 to $45.00.
  • June 1, 2026Funds managed by affiliates of Apollo invested about $1.25 billion in convertible preferred equity of Medical-Surgical Solutions for a minority interest of about 13%. McKesson keeps control of the business, which it plans to separate.
  • May 7, 2026McKesson reported fiscal 2026 results. Revenue rose 12% to $403.4 billion, adjusted EPS rose 18% to $39.11 and free cash flow was $5.4 billion. The board added $5.0 billion to the share repurchase authorization, and the company started a $2.25 billion accelerated share repurchase. It gave fiscal 2027 adjusted EPS guidance of $43.80 to $44.60 and kept its long-term growth target of 13% to 16%.

Latest news and filings

Last earnings
November 4, 2026 (8-K on sec.gov)
Next earnings
Expected about February 3, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 927653)

Risks

Bull case: Adjusted EPS guidance of $45.60 to $46.40 for fiscal 2027 means 17% to 19% growth, and oncology growth, buybacks and few distribution rivals can keep earnings rising at the long-term target.

  • The stock price expects EPS growth of 13% or more each year for many years. A slower year, a lost large customer or lower profit on branded drugs can lower the multiple that investors pay.
  • McKesson had an estimated opioid litigation liability of $5.2 billion at September 30, 2026, mostly paid through 2038. Some local governments and private plaintiffs are not part of the settlements, and new rulings can add costs.
  • The company is separating Medical-Surgical Solutions, integrating Precision Medicine Group and investing in Option Care Health at the same time. Delays, charges or weak results from these deals can lower returns.
  • After the cybersecurity incident of August 2026, class actions allege that the company did not protect health and personal data. Settlements or new rules on data protection can add costs.
  • U.S. drug pricing rules can change the profit that distributors earn on branded and generic drugs.
  • Two federal programs can lower what Medicare pays for cancer drugs given in a doctor's office (Medicare Part B). McKesson's Oncology & Multispecialty segment, with revenue of $15.0 billion in Q2 fiscal 2027, sells these drugs and supports the practices that give them. The first is the Medicare drug price negotiation of the Inflation Reduction Act: its first cycle that includes Part B drugs sets maximum fair prices that take effect on January 1, 2028. The second is the GLOBE model of the CMS Innovation Center (CMMI), a mandatory Part B model with most-favored-nation pricing. CMS published its final rule on September 30, 2026, and the model starts on January 1, 2027 with the collection of international price data. The rule did not exclude cancer drugs. Law firm summaries say drug makers owe the rebates, not distributors, and that CMS projects savings of only $440 million over seven years. McKesson did not name either program on its Q2 fiscal 2027 call and gave no estimate of the effect on its profit. Lower prices can cut the dollar value of drug purchases that the segment handles, and they can press the margins of the practices it supports. These notes are not a forecast.

Key statistics

Market cap
$123B
Shares of Oct 30, 2026
Dividend yield
0.4%
Current annual rate, at the price of Nov 21, 2026
P/E (trailing)
27.6
Price of Nov 21, 2026
EPS (trailing)
$38.75
12 months to Sep 30, 2026
52-week range
$723.68 – $1,121.50
To Nov 12, 2026
Beta
0.28
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
811K
3 months, to Nov 12, 2026

Balance sheet

Cash
$6.5B
Debt
$9.2B
Net debt
$2.7B
Credit line
$5.0B
undrawn, to April 2031

Cash against debt

Cash$6.5B
Debt$9.2B

debt covered by cashnet debt $2.7B

When the debt is due

12 months$794M
Later$8.4B

McKesson funds its working capital mostly with payables to drug makers: drafts and accounts payable were $67.8 billion at September 30, 2026, against receivables of $30.8 billion and inventories of $28.2 billion. Cash was $6.53 billion and debt was $9.21 billion, of which $794 million is due within one year.

Earnings vs free cash flow

Fiscal 2026 (year to March 31, 2026)

  • Adjusted EPS$39.11
  • Free cash flow per share$43.59

Why the two numbers differ

  • Stock-based compensation: adds $1.99 per share. Stock pay of $247 million is not paid in cash, but it is a real cost to owners.
  • Capital spending and capitalized software: takes away $6.00 per share. McKesson spent $436 million on property and equipment and $309 million on capitalized software.
  • Working capital: adds $1.31 per share. Operating assets and liabilities gave $162 million net. It includes $684 million of paid litigation liabilities.

In fiscal 2026, McKesson's free cash flow was $5,410 million, or $43.59 per share, above its adjusted EPS of $39.11. Free cash flow is cash from operations of $6,155 million minus $436 million of property and equipment and $309 million of capitalized software, and McKesson reports the same number. Cash flow is above adjusted earnings because of non-cash costs such as depreciation, amortization and stock pay, and because cash flow is before the share of income that belongs to minority owners. Receivables grew 9% and inventories 5% while revenue grew 12%, and growth in payables of 8% paid for it, so growth did not drain cash. The opioid and other litigation payments are not growth. Free cash flow does not include $3,416 million of acquisitions or $4,750 million of share buybacks.

Dividends

Dividend yield
0.4% (current annual rate, at today’s price of $1,069.43)
Paid per share
$3.40 in the last 12 months (4 payments)
Current annual rate
$3.76 ($0.94 × 4 a year)
Payout ratio
8% of the last fiscal year’s earnings (the year that ended March 31, 2026)
Latest ex-dividend date
September 1, 2026, $0.94 per share

Dividends per share by year

McKesson dividends per share by year
2016
$1.12
2017
$1.24
2018
$1.46
2019
$1.60
2020
$1.66
2021
$1.78
2022
$2.02
2023
$2.32
2024
$2.66
2025
$3.06

From 2020 to 2025, the dividend grew by about 13.0% a year. From 2016 to 2025, the dividend grew by about 11.8% a year.

Source: company filings and market data, read on November 13, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.

Owners and capital return

Large holders

Percent of the shares outstanding, as each filing states it. A filing can be older than the company’s latest report.

What the company says about payouts

McKesson says it expects to keep paying quarterly cash dividends, and the Board decides each amount. In fiscal 2026 it returned $5.1 billion to shareholders, and in April 2026 the Board raised its total buyback authorization to $7.7 billion.

As of · McKesson 10-K for fiscal year ended March 31, 2026

Shareholder yield

5.8% of the market cap came back to shareholders in the 12 months to September 30, 2026: dividends $400M, buybacks $6.8B.

(Dividends + buybacks) / market cap. Cash paid in the last 12 months from the company’s cash flow statements, over today’s market cap. Shares the company issued in the same time are not subtracted. SEC company facts

Share count

  • 1 year: 6.2% fewer shares (124.4M in 2025-09 to 116.7M in 2026-09)
  • 5 years: 25.1% fewer shares (155.8M in 2021-09 to 116.7M in 2026-09)

Diluted average shares of one quarter, as the company reported them at the time. A stock split or a merger inside the span can change the count without a buyback.

Questions about McKesson

What does McKesson do?

McKesson distributes prescription drugs and medical supplies, and it sells services to drug makers, pharmacies and care providers, mostly in the United States and Canada. Its market cap is $123B at the current price of $1,069.43.

When does McKesson report earnings next?

This is an estimate: McKesson may report on February 3, 2027. It last reported results on November 4, 2026.

Is McKesson stock below its intrinsic value?

McKesson stock is pricey. This is general information, not advice.

What changed recently at McKesson?

The latest update is from November 4, 2026. McKesson reported Q2 fiscal 2027 results.

What are the main risks for McKesson?

The stock price expects EPS growth of 13% or more each year for many years. McKesson had an estimated opioid litigation liability of $5.2 billion at September 30, 2026, mostly paid through 2038. The company is separating Medical-Surgical Solutions, integrating Precision Medicine Group and investing in Option Care Health at the same time.

How much debt and cash does McKesson have?

At September 30, 2026, McKesson had $9.2B of debt and $6.5B of cash.

Does McKesson pay a dividend?

Yes. The current annual dividend of McKesson is $3.76 per share. That is a dividend yield of 0.4% at the current price of $1,069.43. In the last 12 months, it paid $3.40 per share (0.3%). The latest ex-dividend date was September 1, 2026.

Valuation against peers

CompanyP/E, last 4 quartersEV/EBITDA, last yearFree cash flow yield, last year10-year average P/EP/E on company guidance
MCKMcKesson27.6x19.4x4.6%21.0x23.2x
SYYSysco20.8xn/a5.0%28.2xn/a
ATOAtmos Energy19.8xn/a-7.3%19.8xn/a
MDLNMedlinen/a17.9x2.7%n/an/a
CORCencora25.2x20.0x5.0%23.9xn/a
Peer median20.8x19.0x3.8%n/an/a
  • MCK trades at 27.6x earnings, 33% above the peer median of 20.8x.
  • Its EV/EBITDA is 19.4x, 2% above the peer median of 19.0x.
  • Its free cash flow yield is 4.6%, 0.8 points above the peer median of 3.8%.
  • Against its own history, the P/E is 31% above its average of 21.0x over 7 profitable years.
  • On the company's own adjusted EPS guidance of $45.60 to $46.40 for fiscal 2027, the P/E is 23.0x to 23.5x.

Guidance source: McKesson earnings release, Nov 4, 2026. The P/E on company guidance uses the middle of the range; an adjusted figure leaves out items the company chooses to leave out.

The peers are the companies on this site most like MCK. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.

Similar companies

  • CORCencoraShares: Regulation and courts
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • CAHCardinal HealthShares: Regulation and courts
    Intrinsic value
    Close to intrinsic value
    Gap
    Slow
  • UNHUnitedHealth GroupShares: Regulation and courts
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • APPAppLovinShares: Regulation and courts
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • PCGPG&EShares: Regulation and courts
    Intrinsic value
    Far below intrinsic value
    Gap
    Will probably not close

Loading your notes…

Read it all? Star MCK or pass, then go on to the next one.